SEC Form 4 · accession 0001209191-17-061539
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Nagler
Officer — SVP, HR & Corp. Affairs
Period of report
Nov 16, 2017
Accepted (ET)
Nov 17, 2017 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $27.39 | Nov 16, 2017 | A | 50,000 | A | — | Nov 16, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.